Kiernan Matthew 4
Research Summary
AI-generated summary
Clene (CLNN) Director Matthew Kiernan Receives Option Awards
What Happened
Matthew Kiernan, a director of Clene Inc. (CLNN), was granted two stock option awards on May 21, 2026 totaling 3,376 options (1,500 and 1,876). The Form 4 records these as derivative acquisitions at $0.00; both options carry an exercise price of $6.81 per share, meaning exercising all options would require about $22,991 (3,376 × $6.81). The 1,500-option award vests in 12 equal monthly installments beginning June 21, 2026; the 1,876-option award vested immediately.
Key Details
- Transaction date: May 21, 2026; Form 4 filed May 22, 2026 (timely filing).
- Reported as awards/grants (code A) of derivatives; acquisition price in filing $0.00.
- Options: 1,500 (vest monthly over 12 months) and 1,876 (vested immediately).
- Exercise price: $6.81 per share for both grants.
- Total options: 3,376; potential cash to exercise all options ≈ $22,991.
- Shares owned after the transaction were not specified in the provided filing excerpt.
- Footnotes: F1 describes the 1,500-option monthly vesting schedule; F2 confirms the 1,876-option vested immediately.
Context
These are option grants (compensation/award), not open-market purchases or sales. Option grants are common for directors and reflect compensation or retention incentives; they do not represent an immediate purchase of stock unless exercised later. There is no indication in this filing that any options were exercised or that any shares were sold.